Evidence map›Paper›PMID 36182768›Full record

ArticleJournal of psychiatric research2022

Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use.

David S Fink, Dvora Shmulewitz, Zachary L Mannes, Malka Stohl, Ofir Livne, Melanie Wall, Deborah S Hasin

Open access · greenAbstract read
In one paragraph

Article in Journal of psychiatric research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. The nosology of addiction as a medical condition: a concise history and review of contemporary perspectives.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  3. Article
  4. Drug interactions in a sample of inpatients diagnosed with cannabis use disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Article
  5. Treatment demand for cannabis use problems: analyses of routine data from 30 European countries.European archives of psychiatry and clinical neuroscience · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

David S FinkNew York State Psychiatric Institute, New York, NY, USA.
Dvora ShmulewitzNew York State Psychiatric Institute, New York, NY, USA; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
Zachary L MannesNew York State Psychiatric Institute, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Malka StohlNew York State Psychiatric Institute, New York, NY, USA.
Ofir LivneNew York State Psychiatric Institute, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Melanie WallNew York State Psychiatric Institute, New York, NY, USA; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.
Deborah S HasinNew York State Psychiatric Institute, New York, NY, USA; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: dsh2@columbia.edu.
New York Psychoanalytic Society and Institute · USColumbia University Irving Medical Center · US

Funding

Substance Abuse Epidemiology Training Program (SAETP) at Columbia UniversityT32DA031099 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DEBORAH S HASIN, Silvia Saboia Martins · 2012 to 2026
$6.1M
Phenotypes for Drug Abuse:Epidemiologic-Genetic ApproachR01DA018652 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI HASIN, DEBORAH S · 2004 to 2018
$5.3M
NIDA NIH HHS R01 DA018652NIDA NIH HHS T32 DA031099
6 · The paper itself

Abstract

The DSM-5 definition of cannabis use disorder (CUD) differs from DSM-IV by combining abuse and dependence criteria (without the legal criterion) and including withdrawal and craving criteria. Information on construct validity of the DSM-5 CUD diagnosis and severity levels is lacking. This study examines the associations between DSM-5 CUD and severity classification and a set of concurrent validators. Adults with problematic substance use were recruited from two settings: a research setting in an urban medical center and a suburban inpatient addiction treatment program. Participants who reported past-year cannabis use (n = 392) were included in this study and completed a semi-structured, clinician-administered diagnostic interview. Regression models estimated the associations between binary DSM-5 CUD and severity levels with a set of validators, including cannabis use variables, psychopathology, and functional impairment. DSM-5 CUD and all severity levels were associated with cannabis use validators, including number of days used, self-reporting that cannabis use was a major problem, and greater cannabis craving. DSM-5 CUD and severe CUD were associated with other psychiatric disorders and social impairment. Findings add information about the validity of DSM-5 CUD diagnosis and severity levels, with severe CUD receiving the strongest support from its association with validators across all domains, as distinct from the mild and moderate CUD measures that were associated with cannabis-specific validators alone. Severe CUD is likely to require more intensive treatment to bolster physical, psychiatric, and social functioning, whereas the mild and moderate severity thresholds provide useful information for identifying less severe disorders for prevention and brief intervention.

Indexed as

HallucinogensMarijuana AbuseSubstance-Related DisordersAdultAntisocial Personality DisorderCravingDiagnostic and Statistical Manual of Mental DisordersHumansHallucinogensCannabis use disorderCannabis use disorder severityConcurrent validityDiagnosisDSM-5

Identifiers

PMID36182768
PMCPMC9590423
OpenAlexW4297880393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.